clinical trial · NCT00649454
Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
HealthyGlipizide and Metformin HCl Tablets 5 mg/500 mgMetaglip® Tablets 5 mg/500 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's glipizide and metformin HCl 5 mg/500 mg tablets to Bristol-Myers Squibb's Metaglip® 5 mg/500 mg tablets following a single, oral 5 mg/500 mg (1 x 5 mg/500 mg) dose administration under fasting conditions.
started
Jun 1, 2005
primary completion
Jun 1, 2005
completion
Jun 1, 2005
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol